2014非小细胞肺癌进展ppt课件.pptVIP

ALK, anaplastic lymphoma kinase; CDKN2A, cyclin-dependent kinase inhibitor 2A; DDR2, discoidin domain-containing receptor 2; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; KIF5B-RET, kinesin family 5B-RET fusion; MCL1, induced myeloid leukemia cell differentiation; NSCLC, non-small cell lung cancer; PDGFRA, alpha-type platelet-derived growth factor receptor; PIK3CA, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog. * ALK, anaplastic lymphoma kinase; EGFR, epidermal growth-factor receptor. * EGFR, epidermal growth factor receptor; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. * ALK, anaplastic lymphoma kinase; CR, complete response; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease. * AUC, area under the curve; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small-cell lung cancer; ORR, overall response rate, OS, overall survival; PFS, progression-free survival. * ITT, intent to treat; NSCLC, non-small-cell lung cancer; RR, response rate; RRR, response rate ratio. * Nab-P/C, albumin bound paclitaxel/carboplatin; NSCLC, non-small-cell lung cancer; P/C, paclitaxel/carboplatin. NSCLC, non-small-cell lung cancer. * * * EGFR, epidermal growth factor receptor; EML4, echinoderm microtubule-associated protein-like 4; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor. NSCLC, non-small cell lung cancer; OS, overall survival; PS, performance status. * ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; WT, wild-type. * EGFR, epidermal growth factor receptor; QoL, quality of life; TKI, tyrosine kinase inhibitor; WT, wild-type. * VEGF Inhibitors Adverse effects Common: hypertension; headaches; renal